Last Update: Aug 19, 2026 A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises ClinicalTrials.gov Identifier: [NCT06439082](https://clinicaltrials.gov/ct2/show/NCT06439082) Novartis Reference Number:CSEG101A2303 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises. Study CSEG101A2303 (SPARKLE) is a Phase III, multicenter, randomized, double-blind study to assess efficacy and safety of crizanlizumab 5 mg/kg versus placebo, with or without hydroxyurea/ hydroxycarbamide therapy (HU/HC), in Sickle Cell Disease patients aged 12 years and older with frequent vaso-occlusive crises (4-12 events in 12 months prior to the screening visit). Participants will be randomized in a 2:1 ratio to the crizanlizumab 5 mg/kg or placebo treatment arm. Central randomization will be stratified by concomitant HU/HC usage (yes/no) and region (South America, North America, and sub-Saharan Africa) at baseline. Condition Sickle Cell Disease Phase Phase3 Overall Status Recruiting Number of Participants354 Start Date Oct 24, 2024 Completion Date Jul 29, 2030 Gender All Age(s) 12 Years - 100 Years (Child, Adult, Older Adult) ## Interventions Biological ### Crizanlizumab Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion. Drug ### Placebo Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion. ## Eligibility Criteria Key Inclusion Criteria: 1\. Participants must be aged 12 years and older on the day of signing informed consent. Adolescents include participants aged 12 to \\<18 years old and adults include participants aged 18 years and older. 2\. Confirmed diagnosis of SCD by Hb electrophoresis or high-performance liquid chromatography (HPLC) (performed locally or by central laboratory if not available locally). All SCD genotypes are eligible. 3\. Experienced 4 to 12 VOCs (refer to Section 8.3.1 for study definition of VOC) that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) within the 12 months prior to the screening visit. Baseline VOCs are determined by medical history and are required to be documented at source. 4\. If the participant is on HU/HC, they must be taking it for at least 6 months and at stable dose for at least 3 months prior to the Screening visit and plan to continue taking it at the same dose and schedule until at least the participant has reached 52 weeks of the planned study treatment. Participants who have initiated HU/HC 6-12 months prior to the screening visit must have evidence of insufficient control of acute pain despite initiation. These participants must have a cumulative of 4-12 VOCs in the 12 months prior to the screening period, with at least 2 during the last 6 months while on HU/HC. If receiving erythropoietin stimulating agent, the participant must have been receiving the drug for at least 6 months prior to screening visit and plan to continue taking the drug at the same dose and schedule until the participant has reached 52 weeks of the planned study treatment. Participants who have not been receiving HU/HC, and/or erythropoietin stimulating agent must not have received it for at least 6 months prior to screening visit. Key Exclusion Criteria: 1\. Fewer than 4 or more than 12 VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) within the 12 months prior to screening visit as determined by medical history and documented at source. 2\. History of stem cell transplant and/or gene therapy. 3\. Received blood products within 30 days prior to Week 1 Day 1 dosing. 4\. Any documented history of a clinical stroke or intracranial hemorrhage, or an uninvestigated neurologic finding within the past 12 months before screening visit. Silent infarct only present on imaging is not excluded. 5\. Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) and/or planning to undergo an exchange transfusion during the duration of the study; episodic transfusion in response to worsened anemia or VOC is permitted. 6\. Contraindication or hypersensitivity to any drug or metabolites from similar class as study drug or to any excipients of the study drug formulation. History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction. Brazil #### Novartis Investigative Site Recruiting Sao Jose Rio Preto,São Paulo,15090-000,Brazil #### Novartis Investigative Site Recruiting São Luís,Maranhão,65020-070,Brazil #### Novartis Investigative Site Recruiting Campinas,São Paulo,13083-970,Brazil #### Novartis Investigative Site Recruiting Ribeirão Preto,São Paulo,14048-900,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,01232-010,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,08270-070,Brazil #### Novartis Investigative Site Recruiting Salvador,Estado de Bahia,41253-190,Brazil Colombia #### Novartis Investigative Site Recruiting Cali,Valle del Cauca Department,760032,Colombia #### Novartis Investigative Site Recruiting Cali,Valle del Cauca Department,760046,Colombia #### Novartis Investigative Site Recruiting Montería,230001,Colombia #### Novartis Investigative Site Recruiting Medellín,Antioquia,050001,Colombia Kenya #### Novartis Investigative Site Recruiting Ahero,Kisumu County,40100,Kenya #### Novartis Investigative Site Recruiting Kisumu,40103,Kenya #### Novartis Investigative Site Recruiting Siaya,40600,Kenya Uganda #### Novartis Investigative Site Recruiting Masaka,001,Uganda #### Novartis Investigative Site Recruiting Kampala,101,Uganda #### Novartis Investigative Site Recruiting Tororo,10102,Uganda United States #### Ctr for Inherited Blood Disorders Recruiting Orange,California,92868,United States ###### Emily Lopez Email: ###### Vanessa Salinas #### Uni of Illinois Hospital and HSC Recruiting Chicago,Illinois,60612,United States ###### Santosh Saraf ###### Taif Hassan Email: #### Thomas Jefferson University Me Recruiting Philadelphia,Pennsylvania,19107,United States ###### Katie McDonnell Email: ###### Sanaa Rizk #### University Of Alabama Recruiting Birmingham,Alabama,35233,United States ###### Jeanine Dumas Phone: [+1 205 638 9285]() Email: ###### Chibuzo Churchill Ilonze #### Wake Forest University Baptist Medical Center Recruiting Winston-Salem,North Carolina,27157,United States ###### Julie Fountain Email: ###### Alex George #### Childrens National Hospital Recruiting Washington D.C.,District of Columbia,20010,United States ###### Andrew Campbell ###### Taylor Quinn Phone: [+1 202 476 5000]() Email: #### WCG Sonar Clinical Research Recruiting Riverdale,Georgia,30274,United States ###### Ify Anierobi Email: ###### Anthony Onyegbula #### University of Florida Recruiting Jacksonville,Florida,32209,United States ###### Gabriela Bastidas ###### Tatiana Elias-Grajeda Email: #### Augusta University Georgia Recruiting Augusta,Georgia,30912,United States ###### Abdullah Kutlar ###### Latanya Bowman Phone: [+1 706 721 2941]() Email: #### East Carolina University Recruiting Greenville,North Carolina,27834,United States ###### Beng Fuh ###### Tori Donadio Email: #### Norton Children s Hospital Recruiting Louisville,Kentucky,40202,United States ###### Ashok Raj ###### Meagan Despain Email: #### Spoknwrdclinicaltrials Recruiting Easton,Pennsylvania,18045,United States ###### Anne Murunga Email: ###### Hayman Salib #### The Johns Hopkins University School of Medicine Recruiting Baltimore,Maryland,21205,United States ###### Lydia Pecker ###### Goodness Che Phone: [+1 410 955 2812]() Email: #### Childrens Hospital at Montefiore Recruiting The Bronx,New York,10467,United States ###### Kaitlin Strumph ###### Karen Ireland Phone: [+1 718 741 2384]() Email: #### U of TX Health Science Ct Recruiting Houston,Texas,77030,United States ###### Eyuel Baherey Email: ###### Modupe Idowu #### Southern Specialty Research Recruiting Flowood,Mississippi,39232,United States ###### Sharon Pennington ###### Wendy Thomson Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: [](mailto:) #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: